96 related articles for article (PubMed ID: 2302206)
1. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats.
Subramanyam B; Rollema H; Woolf T; Castagnoli N
Biochem Biophys Res Commun; 1990 Jan; 166(1):238-44. PubMed ID: 2302206
[TBL] [Abstract][Full Text] [Related]
2. Detection of a neurotoxic quaternary pyridinium metabolite in the liver of haloperidol-treated rats.
Ablordeppey SY; Borne RF
Pharmacol Biochem Behav; 1993 Nov; 46(3):739-44. PubMed ID: 8278454
[TBL] [Abstract][Full Text] [Related]
3. Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite.
Subramanyam B; Woolf T; Castagnoli N
Chem Res Toxicol; 1991; 4(1):123-8. PubMed ID: 1912294
[TBL] [Abstract][Full Text] [Related]
4. Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice.
Van der Schyf CJ; Castagnoli K; Usuki E; Fouda HG; Rimoldi JM; Castagnoli N
Chem Res Toxicol; 1994; 7(3):281-5. PubMed ID: 8075357
[TBL] [Abstract][Full Text] [Related]
5. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies.
Rollema H; Skolnik M; D'Engelbronner J; Igarashi K; Usuki E; Castagnoli N
J Pharmacol Exp Ther; 1994 Jan; 268(1):380-7. PubMed ID: 8301579
[TBL] [Abstract][Full Text] [Related]
6. Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event.
Kalgutkar AS; Nguyen HT
Drug Metab Dispos; 2004 Sep; 32(9):943-52. PubMed ID: 15319335
[TBL] [Abstract][Full Text] [Related]
7. Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins.
Castagnoli N; Castagnoli KP; Van der Schyf CJ; Usuki E; Igarashi K; Steyn SJ; Riker RR
Pol J Pharmacol; 1999; 51(1):31-8. PubMed ID: 10389142
[TBL] [Abstract][Full Text] [Related]
8. Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem.
Eyles DW; Avent KM; Stedman TJ; Pond SM
Life Sci; 1997; 60(8):529-34. PubMed ID: 9042387
[TBL] [Abstract][Full Text] [Related]
9. Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP.
Igarashi K; Kasuya F; Fukui M; Usuki E; Castagnoli N
Life Sci; 1995 Nov; 57(26):2439-46. PubMed ID: 8847965
[TBL] [Abstract][Full Text] [Related]
10. Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol.
Subramanyam B; Pond SM; Eyles DW; Whiteford HA; Fouda HG; Castagnoli N
Biochem Biophys Res Commun; 1991 Dec; 181(2):573-8. PubMed ID: 1755839
[TBL] [Abstract][Full Text] [Related]
11. 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies.
Bloomquist J; King E; Wright A; Mytilineou C; Kimura K; Castagnoli K; Castagnoli N
J Pharmacol Exp Ther; 1994 Aug; 270(2):822-30. PubMed ID: 8071874
[TBL] [Abstract][Full Text] [Related]
12. Brain extraction of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]pyridinium ion (HPP+), a neurotoxic metabolite of haloperidol: studies using [3H]HPP+.
Kawashima H; Iida Y; Kitamura Y; Kiyono Y; Magata Y; Saji H
Jpn J Pharmacol; 2002 Aug; 89(4):426-8. PubMed ID: 12233823
[TBL] [Abstract][Full Text] [Related]
13. Increased sensitivity of mice to tremorogenic agents following MPP+.
Wagner GC; Walsh SL
Psychopharmacology (Berl); 1987; 92(4):470-2. PubMed ID: 3114800
[TBL] [Abstract][Full Text] [Related]
14. Central depletion of dopamine in rats by 1-methyl-4-phenylpyridine.
Okada M; Yokotani K; Yamashita M; Ikeda H; Osumi Y
Life Sci; 1989; 45(5):391-9. PubMed ID: 2788790
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway.
Kalgutkar AS; Taylor TJ; Venkatakrishnan K; Isin EM
Drug Metab Dispos; 2003 Mar; 31(3):243-9. PubMed ID: 12584149
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia.
Eyles DW; McLennan HR; Jones A; McGrath JJ; Stedman TJ; Pond SM
Clin Pharmacol Ther; 1994 Nov; 56(5):512-20. PubMed ID: 7955815
[TBL] [Abstract][Full Text] [Related]
17. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes.
Usuki E; Pearce R; Parkinson A; Castagnol N
Chem Res Toxicol; 1996 Jun; 9(4):800-6. PubMed ID: 8831826
[TBL] [Abstract][Full Text] [Related]
18. Formation of pyridinium species of haloperidol in human liver and brain.
Eyles DW; McGrath JJ; Pond SM
Psychopharmacology (Berl); 1996 Jun; 125(3):214-9. PubMed ID: 8815956
[TBL] [Abstract][Full Text] [Related]
19. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
Zuddas A; Fascetti F; Corsini GU; Piccardi MP
Exp Neurol; 1994 May; 127(1):54-61. PubMed ID: 8200437
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
Avent KM; DeVoss JJ; Gillam EM
Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
